Encorafenib

468 interactions 398 cited references

Also sold as: Braftovi Braftovi®

About Encorafenib

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the bod… Read the full Encorafenib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Atazanavir Posaconazole Ranolazine Piperaquine Doravirine Pimozide

36 Contraindicated 392 Major 40 Moderate

All (468) Contraindicated (36) Major (392) Moderate (40)

Major

Encorafenib Etonogestrel Nexplanon Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Etoposide Avopef Reduced etoposide exposure and reduced efficacy of etoposide Details Encorafenib Etrasimod Velsipity Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Encorafenib Etravirine Intelence Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Everolimus Afinitor Reduced everolimus exposure and reduced efficacy of everolimus Details Encorafenib Famotidine Calmicid Increased risk of QT interval prolongation Details Encorafenib Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Encorafenib Felbamate Felbatol Increased risk of QT interval prolongation Details Encorafenib Felodipine Plendil® Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Fexinidazole Increased risk of QT interval prolongation Details Encorafenib Finerenone Kerendia Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Fingolimod Gilenya Increased risk of QT interval prolongation Details Encorafenib Flecainide Tambocor® Increased risk of QT interval prolongation Details Encorafenib Fluoxetine RECONCILE Increased risk of QT interval prolongation Details Encorafenib Fluticasone Aller-Flo Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Formoterol Perforomist Increased risk of QT interval prolongation Details Encorafenib Fosamprenavir Lexiva Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Fosaprepitant Emend Injection Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Foscarnet Foscavir Increased risk of QT interval prolongation Details Encorafenib Fosfomycin Contepo An increased risk of QT interval prolongation Details Encorafenib Fosnetupitant Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Fosphenytoin Cerebyx Reduced encorafenib exposure, reduced efficacy of encorafenib and an increased risk of QT interval prolongation Details Encorafenib Fostemsavir Rukobia Increased risk of torsade de pointes Details Encorafenib Futibatinib Lytgobi Reduced futibatinib exposure and reduced efficacy Details Encorafenib Galantamine Razadyne Increased risk of QT interval prolongation Details Encorafenib Ganaxolone Ztalmy Reduced ganaxolone exposure and reduced efficacy of ganaxolone Details Encorafenib Gatifloxacin Zymaxid Increased risk of QT interval prolongation Details Encorafenib Gemifloxacin Factive Increased risk of QT interval prolongation Details Encorafenib Gepirone Exxua Reduced gepirone exposure; reduced efficacy of gepirone, an increased risk of QT interval prolongation and cardiac arrhythmias Details Encorafenib Gepotidacin Blujepa Reduced gepotidacin efficacy and an increased risk of QT interval prolongation Details Encorafenib Gestodene Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Givinostat Duvyzat Increased risk of QT interval prolongation and torsade de pointes Details Encorafenib Glasdegib Daurismo Increased risk of QT interval prolongation Details Encorafenib Goserelin Increased risk of QT interval prolongation Details Encorafenib Granisetron Increased risk of QT interval prolongation Details Encorafenib Halofantrine Increased risk of QT interval prolongation Details Encorafenib Haloperidol Increased risk of QT interval prolongation Details Encorafenib Histrelin Supprelin Increased risk of QT interval prolongation Details Encorafenib Hydroquinidine Increased risk of QT interval prolongation Details Encorafenib Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.